卡培他滨诱导手足综合征动物模型的建立
发布时间：2018-07-31 16:50
【摘要】：目的卡培他滨作为一线化疗药物,诱发手足综合征(hand foot syndrome,HFS)的发病率高,但目前HFS的发病机制不清,临床研究过程中相关标本(尤其是病理标本)难以获得。本研究旨在建立理想卡培他滨诱导HFS大鼠模型,从而应用于卡培他滨致HFS的发病机制及防治措施的研究中。方法 SD雌性大鼠115只,按实验需求分为A、B、C、D、E、F 6组,A组以200mg/kg卡培他滨灌胃连续7d,2次/d,休息3d。B组在A组基础上再灌胃7d,建立卡培他滨诱导HFS大鼠模型,C组400mg/kg,灌胃连续7d,2次/d。D、E组为空白对照组,F组为正常对照组。通过图像对比,HE染色和天狼猩红染色等方法对比评价所建立HFS模型。结果 A组HFS发生率为40.0%,B组总发病率可达到77.5%,C组HFS发病率可达到80.0%,D、E、F组HFS发病率均为0。经统计学分析,A组与B、C两组相比HFS发病率差异有统计学意义,P0.001;B组与C组相比HFS发病率差异无统计学意义,P=1.000。但是,C组大鼠第1个周期平均体质量(F=6.779 3,P0.001)与第2个周期平均体质量(F=23.611 1,P0.001)均明显低于B组。结论与200mg/kg卡培他滨灌胃,给药2个周期相比,200 mg/kg卡培他滨灌胃给药1个周期,HFS的发病率较低,而400mg/kg卡培他滨灌胃给药2个周期,并不能增加造模成功率,而且增加了造模成本,引起不良反应发生增加。因此,200mg/kg卡培他滨灌胃给药2个周期的造模方法,在不增加造模成本的同时,既保证了高的造模成功率(77.5%),也不会致模型大鼠出现严重的给药不良反应,能够建立质量较高的卡培他滨诱导HFS的大鼠模型。
[Abstract]:Objective capecitabine, as a first-line chemotherapeutic drug, has a high incidence of (hand foot syndrome induced by (hand foot syndrome, but the pathogenesis of HFS is not clear, and it is difficult to obtain relevant specimens (especially pathological ones) in the course of clinical research. The purpose of this study was to establish an ideal capecitabine-induced HFS rat model and to apply it to the study of the pathogenesis and prevention and treatment of capecitabine-induced HFS. Methods 115 SD female rats, According to the experimental requirements, the rats were divided into two groups: group A: 200mg/kg capecitabine was perfused intragastrically twice a day for 7 consecutive days. The rest 3d.B group was reperfused on the basis of group A for 7 days. The rat model of capecitabine induced by capecitabine was established in group C (400mg / kg). The rats in group C received oral administration of capecitabine twice times for 7 days as control group. The control group was the normal control group. The HFS model was established by image contrast HE staining and sirius red staining. Results the incidence of HFS in group A was 40.0% and the total incidence of HFS in group B was 77.5%. The incidence of HFS in group C was 80.00.The incidence of HFS in group F was 0. The incidence of HFS in group A was significantly higher than that in group B (P 0.001). There was no significant difference in incidence of HFS between group B and group C (P = 1.000). However, the mean body weight of the first cycle (FV 6.779 3) and the second cycle (FN 23.611 1 / P0.001) in group C were significantly lower than those in group B (P 0.001), but the mean body mass of group C was significantly lower than that of group B (P 0.001). Conclusion compared with 200mg/kg capecitabine for 2 cycles, the incidence of 1 cycle of capecitabine administration is lower than that of 400mg/kg capecitabine for 2 cycles, which can not increase the success rate of model making and increase the cost of model making. The incidence of adverse reactions increased. Therefore, the model method of 200 mg / kg capecitabine for 2 cycles not only guaranteed a high success rate (77.5%), but also did not cause severe adverse drug reactions in model rats. The rat model of HFS induced by capecitabine with high quality was established.
【作者单位】： 河北北方学院研究生院;
【基金】：全军“十二五”中医药重点项目(10ZYZ105) 河北省研究生创新资助项目(285)
【分类号】：R-332;R730.53
，
本文编号：2156204
[Abstract]:Objective capecitabine, as a first-line chemotherapeutic drug, has a high incidence of (hand foot syndrome induced by (hand foot syndrome, but the pathogenesis of HFS is not clear, and it is difficult to obtain relevant specimens (especially pathological ones) in the course of clinical research. The purpose of this study was to establish an ideal capecitabine-induced HFS rat model and to apply it to the study of the pathogenesis and prevention and treatment of capecitabine-induced HFS. Methods 115 SD female rats, According to the experimental requirements, the rats were divided into two groups: group A: 200mg/kg capecitabine was perfused intragastrically twice a day for 7 consecutive days. The rest 3d.B group was reperfused on the basis of group A for 7 days. The rat model of capecitabine induced by capecitabine was established in group C (400mg / kg). The rats in group C received oral administration of capecitabine twice times for 7 days as control group. The control group was the normal control group. The HFS model was established by image contrast HE staining and sirius red staining. Results the incidence of HFS in group A was 40.0% and the total incidence of HFS in group B was 77.5%. The incidence of HFS in group C was 80.00.The incidence of HFS in group F was 0. The incidence of HFS in group A was significantly higher than that in group B (P 0.001). There was no significant difference in incidence of HFS between group B and group C (P = 1.000). However, the mean body weight of the first cycle (FV 6.779 3) and the second cycle (FN 23.611 1 / P0.001) in group C were significantly lower than those in group B (P 0.001), but the mean body mass of group C was significantly lower than that of group B (P 0.001). Conclusion compared with 200mg/kg capecitabine for 2 cycles, the incidence of 1 cycle of capecitabine administration is lower than that of 400mg/kg capecitabine for 2 cycles, which can not increase the success rate of model making and increase the cost of model making. The incidence of adverse reactions increased. Therefore, the model method of 200 mg / kg capecitabine for 2 cycles not only guaranteed a high success rate (77.5%), but also did not cause severe adverse drug reactions in model rats. The rat model of HFS induced by capecitabine with high quality was established.
【作者单位】： 河北北方学院研究生院;
【基金】：全军“十二五”中医药重点项目(10ZYZ105) 河北省研究生创新资助项目(285)
【分类号】：R-332;R730.53
，
本文编号：2156204
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2156204.html
